Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs ITI-333 (Primary)
- Indications Mood disorders; Pain; Substance-related disorders
- Focus Adverse reactions
- Sponsors Intra-Cellular Therapies
- 10 Mar 2023 The protocol was amended to decrease in number of arms from 8 to 6. Decrase in frequency of dose by 2 and also decrease in dose of drug.
- 11 Apr 2022 Status changed from recruiting to completed.
- 09 Nov 2021 According to an Intra-Cellular Therapies media release, results from this study are anticipated in the fourth quarter of 2021.